ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

ClinicalTrials.gov ID: NCT05318573

Public ClinicalTrials.gov record NCT05318573. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 12:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a Study With Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Study identification

NCT ID
NCT05318573
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Industry
Enrollment
120 participants

Conditions and interventions

Interventions

  • FF-10832 Drug
  • Pembrolizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2022
Primary completion
Apr 30, 2029
Completion
Oct 31, 2029
Last update posted
Sep 3, 2025

2022 – 2029

United States locations

U.S. sites
23
U.S. states
19
U.S. cities
22
Facility City State ZIP Site status
Cancer and Blood Speciality Clinic Long Beach California 90806
Sharp Memorial Hospital (Oncology Clinical Research) San Diego California 92123
Sibley Memorial Hospital Washington D.C. District of Columbia 20016
University of Kansas Cancer Center - Westwood Westwood Kansas 66205
University of Kentucky Medical Center Lexington Kentucky 40536
University of Louisville Brown Cancer Center Louisville Kentucky 40202
Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) Detroit Michigan 48202
Washington University School of Medicine, Center for Adv Medicine St Louis Missouri 63110
Nebraska Cancer Specialists - Legacy Omaha Nebraska 68130
Comprehensive Cancer Centers of Nevada - Southern Hills Las Vegas Nevada 89148
Atlantic Health System / Morristown Medical Center Morristown New Jersey 07960
NYU Langone Health New York New York 10016
Icahn School of Medicine at Mount Sinai New York New York 10029
TriHealth Cancer Institute; Good Samaritan Hospital Cincinnati Ohio 45220
Providence Cancer Institute Franz Clinic Portland Oregon 97213
Hospital of the Univ of Pennsylvania Perlman Center Philadelphia Pennsylvania 19104
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232
Medical University of South Carolina Charleston South Carolina 29425
Avera Cancer Institute Sioux Falls South Dakota 57105
Sarah Cannon Research Institute Nashville Tennessee 37203
University of Texas Southwestern Medical Center Dallas Texas 75235
Virginia Cancer Specialists, PC Fairfax Virginia 22031
University of Wisconsin Clinical Science Center Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05318573, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 3, 2025 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05318573 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →